Ingenol Angelate Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ingenol angelate, isolated from Euphorbia species, is prone to rearrangement among its isoforms, particularly when formulated for topical application, leading to instability and reduced effectiveness in treating skin cancers due to varying solubilities and pH sensitivity.
Innovation Solution
A stable formulation of ingenol angelate is achieved by dissolving it in a pharmaceutically acceptable aprotic solvent with a miscible acidic buffer, maintaining an apparent pH of no greater than 4.5, which inhibits rearrangement and ensures stability, particularly using benzyl alcohol and citrate buffer, to maintain the preferred isoform 'b' (I3A) for effective topical application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ingenol angelate is formulated in conventional solvents, then solubility is improved, but isoform rearrangement increases leading to instability
Solution Approach 1:
The patent applies parameter changes by adjusting the pH to be no greater than 4.5 and selecting specific aprotic solvents, which fundamentally changes the chemical environment to prevent isoform rearrangement while maintaining solubility. This parameter optimization resolves the contradiction between solubility and stability.
Solution Approach 2:
The formulation uses a composite approach by combining aprotic solvents with acidic buffers (pH ≤ 4.5), creating a synergistic system where the aprotic nature prevents rearrangement and the acidic environment maintains solubility. This composite formulation strategy resolves the contradiction between the two opposing requirements.
2Speed
If ingenol angelate is stored at higher temperatures to improve dissolution rate, then dissolution speed is improved, but rearrangement to other isoforms increases
Solution Approach 1:
The patent changes the chemical parameters by using aprotic solvents and controlling pH ≤ 4.5, which allows dissolution to proceed at acceptable rates without triggering the thermal rearrangement that would otherwise occur. This parameter modification resolves the contradiction between dissolution speed and compositional stability.
3Reliability
If systemic treatments are used to treat skin cancer, then treatment efficacy is improved, but exposure of healthy cells to cytotoxic chemicals increases
Solution Approach 1:
The patent applies local quality by designing a topical formulation that delivers ingenol angelate specifically to skin lesions. The aprotic solvent system ensures the drug remains stable and active at the application site, providing localized treatment efficacy while avoiding systemic distribution and the associated toxicity to healthy cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a stable and effective topical treatment for skin cancers by minimizing isoform rearrangement, ensuring prolonged stability and maintaining therapeutic efficacy, with enhanced patient acceptance by reducing systemic exposure and improving localized delivery.
Implementation Method 1
maintaining an apparent pH of no greater than 4.5, which inhibits rearrangement and ensures stability
Implementation Method 2
ingenol angelate can be solubilised, substantially without rearrangement between isoforms, in an acceptable, aprotic solvent
Data Source
AI summary
Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.